- Cannabix Technologies (CSE:BLO) delivered its Marijuana Breath Test (MBT) devices to a workplace drug and alcohol testing clinic in eastern Canada through an authorized reseller
- The delivery reflects growing interest from testing clinics and employers in breath-based THC tools that better assess recent cannabis use for workplace safety and compliance
- Breath-based testing is being adopted across safety-sensitive industries as a complement to traditional methods, particularly for post-incident, reasonable-cause, and fitness-for-duty testing
- Cannabix stock (CSE:BLO) opened trading at $0.73
Cannabix Technologies (CSE:BLO) has delivered its Marijuana Breath Test (MBT) products to a drug and alcohol testing clinic serving workplace clients in eastern Canada. The delivery was completed through an authorized reseller.
The clinic provides drug testing and process services to a range of clients, including commercial companies, private businesses, government agencies, and individual customers. The addition of Cannabix’s breath-based THC testing equipment reflects growing interest among professional testing clinics in technologies designed to assess recent cannabis use more accurately in workplace and occupational settings.
In a media release, Cannabix stated that the delivery aligns with increasing demand from employers, regulators, and insurers for tools that can support timely and defensible decision-making related to workplace safety. Breath-based THC testing is being evaluated as a complement to existing testing methods, particularly in environments where current-use assessment is considered important.
Shift in workplace testing needs
Workplace drug and alcohol testing clinics play a central role in helping employers meet safety, compliance, and legal requirements. Cannabis legalization and evolving workplace policies, however, have introduced new challenges for these service providers.
Traditional urine and oral fluid tests can detect evidence of cannabis exposure days or even weeks after use. While effective for identifying prior consumption, these methods may offer limited insight into whether an individual has used cannabis recently. This limitation can complicate post-incident, reasonable-cause, or fitness-for-duty assessments and can lead to disputes when test results are challenged by employees, unions, or legal representatives.
As a result, testing clinics are increasingly under pressure to adopt tools that better align with real-world workplace safety decisions. Industry participants note that clinics must balance scientific credibility, operational efficiency, and neutrality when advising employers and managing testing programs.
Role of breath-based THC testing
Cannabix positions its MBT as a non-invasive, breath-based testing option intended to measure recent cannabis use within a shorter detection window compared with traditional methods. According to the company, the technology is designed for use in clinic-based or on-site testing environments and produces objective results that can be confirmed through laboratory-based analysis using liquid chromatography–mass spectrometry (LC-MS).
Potential advantages cited by Cannabix include improved donor experience due to breath-based collection, reduced logistical complexity, and a testing timeframe that more closely aligns with recent-use considerations. For clinics, the company says this approach may help mitigate legal and reputational risks associated with results that reflect historical cannabis exposure rather than recent use.
The company added that interest in breath-based testing is emerging across diverse industries, particularly those with safety-sensitive operations. These include transportation, industrial services, construction, energy, and other sectors where impairment-related risk management is a priority.
Implications for testing clinics and employers
By incorporating breath-based THC testing, clinics may be able to expand their service offerings while addressing employer demand for more relevant and actionable information. Supporters of the technology argue that it can enhance post-incident investigations, reasonable-cause testing, and deterrence programs by focusing on recent use rather than past exposure.
Cannabix emphasized that its MBT is intended to complement, not replace, established testing protocols. The company views professional drug and alcohol testing clinics as a key adoption channel, given their established relationships with employers and their familiarity with regulatory and jurisdictional requirements.
From an industry perspective, the delivery to the eastern Canada clinic highlights ongoing experimentation with new testing modalities as workplaces adapt to changing cannabis policies. Whether breath-based THC testing becomes a widely adopted adjunct standard will depend on regulatory acceptance, operational performance, and employer demand.
About Cannabix
Cannabix Technologies develops marijuana and alcohol breath technologies for workplaces, law enforcement and other safety-sensitive settings.
Cannabix stock (CSE:BLO) opened trading at $0.73 and has risen 18 per cent since this time last year.
Join the discussion: Find out what investors are saying about this cannabis breathalyzer stock on the Cannabix Technologies Inc. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.